Dan Li1, Marita C Bautista1, Sheng-Fang Jiang2, Paras Daryani1, Marilyn Brackett3, Mary Anne Armstrong2, Yun-Yi Hung2, Debbie Postlethwaite2, Uri Ladabaum4. 1. Department of Medicine and Gastroenterology, Kaiser Permanente Northern California, Santa Clara, California, USA. 2. Division of Research, Kaiser Permanente Northern California, Oakland, California, USA. 3. Department of Pathology, Kaiser Permanente Northern California, Oakland, California, USA. 4. Department of Medicine, Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Palo Alto, California, USA.
Abstract
OBJECTIVES: Gastric intestinal metaplasia and dysplasia are precursor lesions for adenocarcinoma. The risks of progression to malignancy from these lesions are not well characterized, particularly in the US populations. METHODS: We identified 4,331 Kaiser Permanente Northern California members who were diagnosed with gastric intestinal metaplasia or dysplasia between 1997 and 2006 and followed them through December 2013. The incident rates of gastric adenocarcinoma, relative risks in comparison with the Kaiser Permanente general population, and predictors of progression to malignancy were investigated. RESULTS: Among 4,146 individuals with gastric intestinal metaplasia and 141 with low-grade dysplasia with 24,440 person-years follow-up, 17 and 6 cases of gastric adenocarcinoma were diagnosed, respectively, after 1 year from the index endoscopy. The incidence rate of gastric adenocarcinoma was 0.72/1,000 person-years in patients with intestinal metaplasia, with a relative risk of 2.56 (95% confidence interval (CI) 1.49-4.10) compared with the Kaiser Permanente member population, and 7.7/1,000 person-years for low-grade dysplasia, with a relative risk of 25.6 (95% CI, 9.4-55.7). The median time for gastric intestinal metaplasia to progress to adenocarcinoma was 6.1 years, and for low-grade dysplasia, 2.6 years. Hispanic race/ethnicity and history of dysplasia were associated with significantly higher risk of progression to gastric adenocarcinoma. CONCLUSIONS: Gastric intestinal metaplasia and dysplasia are significant predictors for gastric adenocarcinoma. The low risk for malignancy associated with intestinal metaplasia does not support routine endoscopic surveillance. However, surveillance should be considered in patients at higher risks, including those with suspicious endoscopic features, presence of dysplasia, and Hispanic race/ethnicity.
OBJECTIVES:Gastric intestinal metaplasia and dysplasia are precursor lesions for adenocarcinoma. The risks of progression to malignancy from these lesions are not well characterized, particularly in the US populations. METHODS: We identified 4,331 Kaiser Permanente Northern California members who were diagnosed with gastric intestinal metaplasia or dysplasia between 1997 and 2006 and followed them through December 2013. The incident rates of gastric adenocarcinoma, relative risks in comparison with the Kaiser Permanente general population, and predictors of progression to malignancy were investigated. RESULTS: Among 4,146 individuals with gastric intestinal metaplasia and 141 with low-grade dysplasia with 24,440 person-years follow-up, 17 and 6 cases of gastric adenocarcinoma were diagnosed, respectively, after 1 year from the index endoscopy. The incidence rate of gastric adenocarcinoma was 0.72/1,000 person-years in patients with intestinal metaplasia, with a relative risk of 2.56 (95% confidence interval (CI) 1.49-4.10) compared with the Kaiser Permanente member population, and 7.7/1,000 person-years for low-grade dysplasia, with a relative risk of 25.6 (95% CI, 9.4-55.7). The median time for gastric intestinal metaplasia to progress to adenocarcinoma was 6.1 years, and for low-grade dysplasia, 2.6 years. Hispanic race/ethnicity and history of dysplasia were associated with significantly higher risk of progression to gastric adenocarcinoma. CONCLUSIONS:Gastric intestinal metaplasia and dysplasia are significant predictors for gastric adenocarcinoma. The low risk for malignancy associated with intestinal metaplasia does not support routine endoscopic surveillance. However, surveillance should be considered in patients at higher risks, including those with suspicious endoscopic features, presence of dysplasia, and Hispanic race/ethnicity.
Authors: E Fontham; D Zavala; P Correa; E Rodriguez; F Hunter; W Haenszel; S R Tannenbaum Journal: J Natl Cancer Inst Date: 1986-04 Impact factor: 13.506
Authors: W H Chow; W J Blot; T L Vaughan; H A Risch; M D Gammon; J L Stanford; R Dubrow; J B Schoenberg; S T Mayne; D C Farrow; H Ahsan; A B West; H Rotterdam; S Niwa; J F Fraumeni Journal: J Natl Cancer Inst Date: 1998-01-21 Impact factor: 13.506
Authors: Marita C Bautista; Sheng-Fang Jiang; Mary Anne Armstrong; Sanjay Kakar; Debbie Postlethwaite; Dan Li Journal: Dig Dis Sci Date: 2014-10-30 Impact factor: 3.199
Authors: Frederik Hvid-Jensen; Lars Pedersen; Asbjørn Mohr Drewes; Henrik Toft Sørensen; Peter Funch-Jensen Journal: N Engl J Med Date: 2011-10-13 Impact factor: 91.245
Authors: M B Fennerty; J C Emerson; R E Sampliner; D L McGee; L J Hixson; H S Garewal Journal: Cancer Epidemiol Biomarkers Prev Date: 1992 May-Jun Impact factor: 4.254
Authors: David K van der Poorten; Duncan McLeod; Golo Ahlenstiel; Scott Read; Avelyn Kwok; Cositha Santhakumar; Milan Bassan; Suzanne Culican; David Campbell; Sue W J Wong; Louise Evans; Bilel Jideh; Alisa Kane; Constance H Katelaris; Karuna Keat; Yanna Ko; Jessie A Lee; Sandhya Limaye; Ming Wei Lin; Ari Murad; Martina Rafferty; Dan Suan; Sanjay Swaminathan; Sean D Riminton; Catherine Toong; Lucinda J Berglund Journal: J Clin Immunol Date: 2018-09-15 Impact factor: 8.317
Authors: Monika Laszkowska; Han Truong; Adam S Faye; Judith Kim; Sarah Xinhui Tan; Francesca Lim; Julian A Abrams; Chin Hur Journal: Dig Dis Sci Date: 2021-10-17 Impact factor: 3.487
Authors: Stuart J Spechler; Juanita L Merchant; Timothy C Wang; Parakrama Chandrasoma; James G Fox; Robert M Genta; James R Goldenring; Yoku Hayakawa; Ernst J Kuipers; Pauline K Lund; Frank McKeon; Jason C Mills; Robert D Odze; Richard M Peek; Thai Pham; Jianwen Que; Anil K Rustgi; Nicholas J Shaheen; Ramesh A Shivdasani; Rhonda F Souza; Peter Storz; Andrea Todisco; David H Wang; Nicholas A Wright Journal: Gastroenterology Date: 2017-06-03 Impact factor: 33.883